Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Awakn Starts Patient Screening For Alcohol Disorder Trial with AWKN-001
Details : AWKN-001 (ketamine) is an investigational consisting of an N-methyl-D-aspartate receptor-modulating drug, a novel medication-assisted treatment for severe AUD.
Product Name : AWKN-001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 08, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable